Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Episodes
215 episodes
The best biotech conversations you missed this summer
Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months.W...
Rewriting the rules of genetic medicine with tRNA therapeutics
Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a di...
How Evox Therapeutics is targeting CNS diseases with exosomes
Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced medicines from ever reaching it. That's now beginning to change. The recen...
BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech
Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026.Joining us is Stuart Medina of Asebio, who will take us inside this landmark gathering. For the first time and i...
Beyond biology: Nanobiotix's physics-first approach to cancer
What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genu...
How Cancer Research Horizons is building the future of childhood cancer medicines
Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, re...
Why Western pharma is sleeping on China's circular RNA revolution
RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be ...
Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's
Today we welcome Gene Mack, President and CEO of Gain Therapeutics. With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and d...
This nonprofit is building the ecosystem to cure epidermolysis bullosa
Epidermolysis bullosa, or EB, is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blisters and open wounds. No cure. And for most of its history, very little ser...
How BIO-Europe is expanding beyond dealmaking in 2026
The life sciences industry has always had one great meeting place, a few days in November where the deals get done, the partnerships form, and the direction of the industry quietly shifts. For more than three decades, that place has been
Turning cancer cell dependencies into targeted therapies
Today I’m delighted to welcome Andy Parker, CEO of Step Pharma.With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, andventure capital, Andy has led Step Pharma since 2019. The...
The first PROTAC is here. What comes next in protein degradation?
Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in medicine.Arvinas is pioneering a technology called PROTAC pro...
De-risking neurology drug development with better mouse models
Today we welcome Brandy Wilkinson, CEO of GemPharmatech, and Rikki Feng, the company’s Neuroscience Pipeline Leader. Our discussion focuses on a persistent challenge in drug development: ne...
BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler
This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceutical companies and investors in partnering meetings, all to advance and f...
Advancing corticosteroids and hormonal therapies for supply and scale
Today we’re diving into the world of corticosteroids and hormonal therapies — essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine disorders. These molecules may be decades old, but their manufactur...
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
Welcome to episode 200!Today I’m delighted to welcome back a very special guest: Joachim Eeckhout, the co-founder of Labiotech, co-owner of Knowbio, and founder of The Science Marketer.Joachim tells the Labiotech story, one of vis...
World MS Day Special: Immunic reveals new hope for progressive MS
Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics. With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sc...
The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data
Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of
Freeze variability, not progress: strengthen your cell therapy supply chain from the start
Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Stren...
Making labs smarter for scientific breakthroughs
Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. Ryan's journey spans groundbrea...
How Epicrispr is leveraging CRISPR without cutting DNA
This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr.Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s propri...
Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases
Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics.A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he fo...
Argobio: the venture model building Europe’s next biotech champions
Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in...
Multi-agent AI delivers reliable and scalable insights for single-cell omics
Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data.Our guest is Parashar Dhapola, co-founder and CEO of